The End of
Trial-and-Error Psychiatry.
We are building the diagnostic platform to enable precision psychiatry at scale.
Our technology decodes novel brain biomarkers into objective guidance for clinical treatment, transforming patient care.
The Biggest Blind Spot in Modern Medicine.
Every major field of medicine has its objective tools—cardiology has the ECG, oncology has imaging, and infectious disease has the PCR test. Yet psychiatry, a $600B+ global industry, has none. This is the biggest blind spot in modern medicine, and it leads directly to a trial-and-error approach where 50% of patients fail their first prescribed treatment.
Pioneering a New Standard of Care with a Predictive Diagnostic Platform for Precision Psychiatry.
Satori Bio is creating the foundational platform for a new era of mental health: one that is predictive, not reactive. Our proprietary AI analyzes scalable EEG data to identify which patients will respond to a specific therapy before treatment begins. This gives clinicians the objective guidance to personalize care, dramatically improve remission rates, and avoid futile treatments. We are answering the most critical question in psychiatry: What is the optimal treatment pathway for each patient?
Contact
Satori Bio is a pre-seed stage company. For investor or partnership inquiries, please reach out to: